BackBioCardia - Warrants (26/07/2022) Overview
BioCardia Inc. - Warrants (26/07/2022)

BioCardia - Warrants (26/07/2022) Return on Equity

BioCardia - Warrants (26/07/2022) (BCDAW) has a ROE of 729.36%, above the Healthcare sector average of 29.39%.

Get informed when a big investor buys or sells

+ Follow

ROE

729.36%

Return on Equity

729.36%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

BioCardia - Warrants (26/07/2022) (BCDAW) FAQ

The latest ROE for BCDAW is 729.36%. That is above the Healthcare sector average of 29.39%. Investors often review this figure alongside BioCardia - Warrants (26/07/2022)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, BCDAW currently prints 729.36% for ROE, while the sector average sits near 29.39%. That is roughly 2381.7% above the sector mean. Large gaps often invite a closer look at BioCardia - Warrants (26/07/2022)'s growth, margins, and balance sheet.

Return on Equity shows how effectively BioCardia - Warrants (26/07/2022) converts resources into returns. At 729.36%, BCDAW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BCDAW's ROE (729.36%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BioCardia - Warrants (26/07/2022)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.